Dolutegravir
Highest phase reached
Approved
Drug type
Small molecule
First approval year
2013
- First approval year
- 2013
- Listing at source
- Listed
- Highest phase reached
- Approved
- Drug type
- Small molecule
- Drug name
- Dolutegravir
- Molecular weight
- 419.38
- Structure (SMILES)
- C[C@@H]1CCO[C@H]2Cn3cc(C(=O)NCc4ccc(F)cc4F)c(=O)c(O)c3C(=O)N12
- (4R,12.ALPHA.S)-N-((2,4-DIFLUOROPHENYL)METHYL)-7-HYDROXY-4-METHYL-6,8-DIOXO-3,4,6,8,12,12.ALPHA.-HEXAHYDRO-2H-PYRIDO(1',2':4,5)PYRAZINO(2,1-.BETA.)(1,3)OXAZINE-9-CARBOXAMIDE
- 4r 12 alpha s n 2 4 difluorophenyl methyl 7 hydroxy 4 methyl 6 8 dioxo 3 4 6 8 12 12 alpha hexahydro 2h pyrido 1 2 4 5 pyrazino 2 1 beta 1 3 oxazine 9 carboxamide
- dolutegravir
- Dolutegravir
- dolutegravir [INN]
- DOLUTEGRAVIR [MI]
- DOLUTEGRAVIR [USAN]
- DOLUTEGRAVIR [VANDF]
- Dolutegravir [WHO-DD]
- dolutegravir dtg 50 mg orally bid 12 hours apart plus tdf 3tc
- dolutegravir inn
- dolutegravir mi
- dolutegravir usan
- dolutegravir vandf
- dolutegravir who dd
- dtg
- DTG
- DTG 50 mg
- DTG 50 mg BID
- DTG film-coated tablets
- DTG granules for suspension
- DTG Tablet
- gsk 1349572
- GSK 1349572
- GSK-1349572
And 9 more, listed on the interactive page.
- CAS registry numbers
- 1051375-16-6
- ChEMBL ID
- CHEMBL1229211
- InChIKey
- RHWKPHLQXYSBKR-BMIGLBTASA-N
- PubChem compound IDs
- 54726191
- RxNorm IDs (RxCUI)
- 1433868
- FDA ingredient codes (UNII)
- DKO1W9H7M1
- J05AJ03
- J05AX12
Sources for recorded values
- Applicant
- VIIV HLTHCARE
- Approval date
- 30 Mar 2022
- Application number
- NDA215413
- Status
- Authorised
- Status date
- 16 Jan 2014
- Authorisation date
- 16 Jan 2014
- Approved indications
- Tivicay is indicated in combination with other anti-retroviral medicinal products for the treatment of Human Immunodeficiency Virus (HIV) infected adults, adolescents and children of at least 6 years of age or older and weighing at least 14 kg. Tivicay is indicated in combination with other anti-retroviral medicinal products for the treatment of Human Immunodeficiency Virus (HIV) infected adults, adolescents and children of at least 4 weeks of age or older and weighing at least 3 kg.
- Product number
- EMEA/H/C/002753
- Authorisation holder
- ViiV Healthcare BV
- Priority medicines scheme
- No
- Generic
- No
- Biosimilar
- No
- Generic medicines
- 0
- Biosimilar medicines
- 0
- Advanced therapy
- No
- Conditional approval
- No
- Additional monitoring
- No
- Accelerated assessment
- No
- Exceptional circumstances
- No
Therapeutic areas
- HIV Infections
European medicines record
- Patents
- 4
- Designations
- 2
- Earliest recorded loss of exclusivity
- 8 Jun 2030
- First in class
- No
- Fast track
- Yes
- Breakthrough designation
- No
- Orphan designation
- No
- Priority review
- Yes
- Orphan exclusivity
- No
- Accelerated approval
- No
- Availability
- Prescription only
- Pharmacology name
- dolutegravir
- Type
- Synthetic organic
- Drug name stem
- -vir; -vir
- Approval recorded by Guide to Pharmacology
- Yes
Administration routes
- Oral
Open Targets mechanisms
- Mechanism
- Human immunodeficiency virus type 1 integrase inhibitor
- Action type
- Inhibitor
- Target
- Human immunodeficiency virus type 1 integrase
DrugCentral mechanisms
- Action type
- Inhibitor
- Gene symbol
- pol
- Protein identifier
- Q7ZJM1
- Organism
- Human immunodeficiency virus 1
- Condition
- HIV Infections
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000180
- Subject identifier
- D015658
- Condition
- Infections
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000544
- Subject identifier
- D007239
- Condition
- Virus Diseases
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000763
- Subject identifier
- D014777
- Condition
- HIV Infections
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000764
- Subject identifier
- D015658
- Condition
- Acquired Immunodeficiency Syndrome
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000765
- Subject identifier
- D000163
- Condition
- Malaria
- Highest recorded phase
- 1
- Condition identifier
- EFO:0001068
- Subject identifier
- D008288
- Condition
- Weight Gain
- Highest recorded phase
- 2
- Condition identifier
- EFO:0004566
- Subject identifier
- D015430
- Condition
- Amyotrophic Lateral Sclerosis
- Highest recorded phase
- 1
- Condition identifier
- MONDO:0004976
- Subject identifier
- D000690
- Condition identifier
- EFO_0000180
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000195
- Condition identifier
- EFO_0000544
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000763
- Condition identifier
- EFO_0000764
- Condition identifier
- EFO_0000765
- Condition identifier
- EFO_0004566
- Highest recorded phase
- 2
- Condition identifier
- EFO_0010125
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0004976
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0005108
- Highest recorded phase
- 4
- Condition identifier
- MONDO_0005109
- Highest recorded phase
- 4
- Condition identifier
- MONDO_0005231
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0005249
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0005344
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0006052
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0012268
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0018076
- Highest recorded phase
- 3
- Event
- abortion
- Reports
- 12
- Reporting signal score
- 27.4087
- Event
- abortion induced
- Reports
- 18
- Reporting signal score
- 24.1507
- Event
- abortion spontaneous
- Reports
- 89
- Reporting signal score
- 143.945
- Event
- acute hepatitis c
- Reports
- 12
- Reporting signal score
- 54.2433
- Event
- anal cancer stage 0
- Reports
- 4
- Reporting signal score
- 22.423
- Event
- birth mark
- Reports
- 41
- Reporting signal score
- 231.842
- Event
- blood hiv rna increased
- Reports
- 130
- Reporting signal score
- 681.87
- Event
- cd4 lymphocytes decreased
- Reports
- 10
- Reporting signal score
- 22.5699
- Event
- congenital skin dimples
- Reports
- 11
- Reporting signal score
- 47.9491
- Event
- congenital umbilical hernia
- Reports
- 54
- Reporting signal score
- 292.911
- Event
- drug interaction
- Reports
- 78
- Reporting signal score
- 29.8856
- Event
- drug resistance
- Reports
- 99
- Reporting signal score
- 218.04
- Event
- drug-induced liver injury
- Reports
- 34
- Reporting signal score
- 37.4347
- Event
- ectopic kidney
- Reports
- 10
- Reporting signal score
- 50.2902
- Event
- endocardial fibroelastosis
- Reports
- 4
- Reporting signal score
- 22.423
- Event
- fall
- Reports
- 5
- Reporting signal score
- 24.3335
- Event
- fibrous histiocytoma
- Reports
- 12
- Reporting signal score
- 48.5425
- Event
- foetal death
- Reports
- 11
- Reporting signal score
- 20.8793
- Event
- hepatitis a
- Reports
- 11
- Reporting signal score
- 37.7581
- Event
- hepatitis c
- Reports
- 21
- Reporting signal score
- 26.4365
- Event
- hepatotoxicity
- Reports
- 27
- Reporting signal score
- 31.5894
- Event
- hiv infection
- Reports
- 9
- Reporting signal score
- 23.6275
- Event
- hydrops foetalis
- Reports
- 8
- Reporting signal score
- 28.6438
- Event
- immune reconstitution inflammatory syndrome
- Reports
- 123
- Reporting signal score
- 456.48
- Event
- live birth
- Reports
- 31
- Reporting signal score
- 80.0394
And 29 more, listed on the interactive page.
- NCT00708110
- NCT00774735
- NCT00950859
- NCT00951015
- NCT01068925
- NCT01098513
- NCT01098526
- NCT01209065
- NCT01214993
- NCT01227824
- NCT01231516
- NCT01231542
- NCT01263015
- NCT01283100
- NCT01328041
- NCT01332565
- NCT01353716
- NCT01366547
- NCT01382238
- NCT01425099
- NCT01449929
- NCT01467518
- NCT01467531
- NCT01498861
- NCT01499199
And 89 more, listed on the interactive page.
- Dose
- 50 mg
- Route
- Oral
- How often
- Once daily
- Hydrogen bond acceptors
- 6
- Hydrogen bond donors
- 2
- Polar surface area
- 100.87
- Calculated partition coefficient (ALogP)
- 1.35
- Calculated partition coefficient (XLogP)
- 2.4
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Rule-of-five violations
- 0
- Rotatable bonds
- 3
- Heavy atoms
- 30
- Molecular formula
- C20H19F2N3O5
- Monoisotopic mass
- 419.12927704
- Natural product
- No
- Recorded assays
- 903
- Active assays
- 87
- Confirmatory
- Other
These details could not be displayed.
Related records
Trials (80)
- A Clinical Study of the Interactions Between Azvudine Tablets (FNC) and Dolutegravir Sodium Tablets (DTG)
- A Clinical Trial to Evaluate the Reversibility of Abacavir/Lamivudine/Dolutegravir CNS-Related Neurotoxicity After Switching to Tenofovir/Alafenamide/Emtricitabine/Darunavir/Cobicistat (TAF/FTC/DRV/c)
- A Dose Ranging Trial of GSK1349572 and 2 NRTI in HIV-1 Infected, Therapy Naive Subjects
- A Drug Interaction Study Evaluating Plasma GSK2248761 and GSK1349572 Pharmacokinetics in Healthy Adult Subjects.
- A Phase 1, Open Label, Placebo-Controlled Study to Evaluate the Effect of GSK1349572 on Iohexol and Para-Aminohippurate Clearance in Healthy Subjects
- A Phase IIIb Study of the Safety, Efficacy, and Tolerability of Switching to a Fixed-dose Combination of Abacavir/Dolutegravir/ Lamivudine From Current Antiretroviral Regimen
- A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study
- A Pilot Study Assessing the Integrase Inhibitor GSK1349572 in HIV-infected Persons With Virus Resistant to Raltegravir
- A Relative Bioavailability and Food-Effect Study of the Fixed Dose Combination of GSK3640254 and Dolutegravir (DTG) in Healthy Participants
- A Study of GSK1349572 Versus Raltegravir (RAL) With Investigator Selected Background Regimen in Antiretroviral-Experienced, Integrase Inhibitor-Naive Adults
- A Study to Evaluate Efficacy, Safety and Tolerability in Antiretroviral Therapy (ART)-Experienced Participants of at Least 50 Years of Age Living With Human Immunodeficiency Virus (HIV) With Virologic Suppression Who Switch to DTG/3TC FDC From BIC/FTC/TAF
- A Study to Evaluate the Effect of Antacid and Multivitamin and Mineral Tablet on the Study Drug GSK1349572
- A Study to Evaluate the Effect of Boceprevir and Telaprevir on Dolutegravir Pharmacokinetics in Healthy Adult Subjects (ING115697).
- A Study to Evaluate the Efficacy, Safety, Participant Choice and Preference of an Oral Once-daily Regimen or a Long-acting Injectable Regimen Every Two Months for Treatment of Human Immunodeficiency Virus (HIV-1) in Adults Who Have Not Previously Taken Antiretroviral Therapy
- A Study to Investigate the Pharmacokinetics, Safety and Tolerability of GSK1349572 (Dolutegravir, DTG) in Healthy Japanese Subjects
- A Trial Comparing GSK1349572 50mg Once Daily to Raltegravir 400mg Twice Daily
- Assess the Effectiveness and Safety of Lipovirtide Combined With Nucleoside Drugs in HIV-infected Patients.
- B-free Multistage Trial
- B/F/TAF to DTG/3TC Switch Study
- Bioequivalence Study of a Fixed-dose Combination (FDC) of Dolutegravir (DTG) and Rilpivirine (RPV)
In development for (5)
- AIDS Phase 3
- Amyotrophic lateral sclerosis Phase 1
- HIV infectious disease Phase 3
- Malaria Phase 1
- Viral infectious disease Phase 3